Optimas Capital’s AbbVie ABBV Stock Holding History

Optimas Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-33,500	Closed	-$5.34M	–	26
2023 Q1	$5.34M	Buy	+33,500	New	+$5.12M	4.48%	6
2022 Q4	–	Sell	-35,300	Closed	-$4.74M	–	31
2022 Q3	$4.74M	Buy	+35,300	New	+$5.07M	3.99%	9

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Optimas Capital's ABBV Position: Q2 2023 in Review

Optimas Capital sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 33,500 shares — an estimated $5.34M sold.

Optimas Capital first reported a position in ABBV in Q3 2022 and held it in 2 quarters. The position peaked at $5.34M in Q1 2023. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

Optimas Capital reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
Optimas Capital sold 33,500 AbbVie shares in Q2 2023, an estimated $5.34M.
Optimas Capital first reported a position in AbbVie in Q3 2022 and held it in 2 quarters.
Optimas Capital's AbbVie position peaked at $5.34M in Q1 2023.
3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Optimas Capital's 13F filing for Q2 2023, filed 11 Aug 2023.